个性化文献订阅>期刊> Cancer gene therapy
 

An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models

  作者 Dharmapuri, S; Aurisicchio, L; Neuner, P; Verdirame, M; Ciliberto, G; La Monica, N  
  选自 期刊  Cancer gene therapy;  卷期  2009年16-5;  页码  462-472  
  关联知识点  
 

[摘要]In vivo electroporation of plasmid DNA (DNA-EP) is an efficient and safe method for vaccines resulting in increased DNA uptake, enhanced protein expression and increased immune responses to the target antigen in a variety of species. To further enhance the efficacy of DNA-EP, we have evaluated the toll-like receptor7 (TLR7) agonist-2, 9, substituted 8-hydroxyadenosine derivative or SM360320-as an adjuvant to vaccines against HER2/neu and CEA in BALB-neuT and CEA transgenic mice (CEA. Tg), respectively. SM360320 induced in vivo secretion of interferon alpha (IFN alpha) and exerted a significant antitumor effect in CEA. Tg mice challenged with a syngenic tumor cell line expressing CEA and an additive effect with a CEA vaccine. Additionally, combination of SM360320 with plasmid encoding the extracellular and transmembrane domain of ratHER2/neu affected the spontaneous tumor progression in BALB-neuT mice treated in an advanced disease setting. The antitumor effect in mice treated with DNA-EP and SM360320 was associated with an anti-CEA and anti- p185(neu) antibody isotype switch from IgG1 to IgG2a. These data demonstrate that SM360320 exerts significant antitumor effects and can act in association with DNA-EP for CEA-positive colon cancer and HER2-positive mammary carcinoma. These observations therefore emphasize the potential of SM360320 as immunological adjuvant for therapeutic DNA vaccines.

 
      被申请数(0)  
 

[全文传递流程]

一般上传文献全文的时限在1个工作日内